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Aim To evaluate clinical relevance of differences between 
escitalopram and citalopram (equimolar) for major depres-
sive disorder.
Methods Review and meta-analysis of comparative ran-
domized controlled trials (RCT). Comparisons were in re-
lation to Montgomery-Asberg depression rating scale 
(MADRS) score reduction at weeks 1 (5 RCTs), 4 (5 RCTs), 6 
(4 RCTs), 8 (5 RCTs), and 24 (1 RCT); proportion of respond-
ers at weeks 2, 4, 6 (2 RCTs for each time point), 8 (5 RCTs), 
and 24 (1 RCT); clinical global impression-severity (CGI-S) 
reduction at weeks 6 (1 RCT), 8 (5 RCTs), and 24 (1 RCT), 
and discontinuation due to adverse events or inefficacy 
during short-term (up to 8 weeks) and medium-term (24 
weeks) treatment.
Results MADRS reduction was greater with escitalopram, 
but 95% confidence intervals (CI) around the mean differ-
ence were entirely or largely below 2 scale points (mini-
mally important difference) and CI around the effect size 
(ES) was below 0.32 (“small”) at all time points. Risk of re-
sponse was higher with escitalopram at week 8 (relative 
risk, 1.14; 95% CI, 1.04 to 1.26) but number needed to treat 
was 14 (95% CI, 7 to 111). All 95% CIs around the mean dif-
ference and ES of CGI-S reduction at week 8 were below 
0.32 points and the limit of “small,” respectively. Data for se-
vere patients (MADRS≥30) are scarce (only 1 RCT), indicat-
ing somewhat greater efficacy (response rate and MADRS 
reduction at week 8, but not CGI-S reduction) of escitalo-
pram, but without compelling evidence of clinically rele-
vant differences. Discontinuations due to adverse events 
or inefficacy up to 8 weeks of treatment were comparable. 
Data for the period up to 24 weeks are scarce and incon-
clusive.
Conclusion Presently, the claims about clinically relevant 
superiority of escitalopram over citalopram in short-to-me-
dium term treatment of major depressive disorder are not 
supported by evidence.
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Due to its common occurrence and burden that it repre-
sents for the affected individuals and the society, depres-
sion is a paramount health care problem (1). Understand-
ably, treatment options have attracted much attention and 
any new treatment showing potential for improvements is 
of a considerable interest.
Citalopram is a generic name for an active compound 
which is a racemic mixture (1:1) of two enantiomers (S-[+] 
and R-[-]) (2). It is a selective serotonin re-uptake inhibitor 
(immediate-release tablets) approved as effective and safe 
in treatment of major depressive disorder (MDD) (3). Re-
uptake inhibition and clinical effects are ascribable to the 
S-(+)-enantiomer (active enantiomer) (2). Escitalopram is a 
generic name for an active compound containing only the 
S-(+)-enantiomer. It was developed (after citalopram) and 
is marketed as effective and safe treatment for MDD by the 
same company that developed citalopram (4). In line with 
the fact that doses of citalopram and escitalopram, equi-
molar by content of the active enantiomer, are also equiv-
alent in terms of its in vivo bioavailability (5), the effective 
doses of citalopram for MDD have two times greater mass 
than the recommended doses of escitalopram (eg, 20 mg 
or 40 mg/d vs 10 mg or 20 mg/d) (3,4).
A number of post-hoc assessments have been released 
over the last 6 years that deal with comparative efficacy/
safety of equimolar (active enantiomer) doses of escitalo-
pram vs citalopram in MDD. They all refer to some or all of 
the same 6 randomized controlled trials: 5 published (6-
10) (the first one in 2002 [6], last one in 2007 [10]) and one 
unpublished trial submitted to the Food and Drug Admin-
istration (code SCT-MD-02) (11). All trials were sponsored 
by the manufacturer. Some of these assessments, au-
thored/co-authored by the company’s employees (2,12-
15, ) or receiving support by the manufacturer (16,) have 
extensively emphasized numerical trends or significant 
differences in some of the trials in favor of escitalopram. 
Some independent reviews (eg 17, ) have also empha-
sized that, in comparison with most of the other newer 
antidepressants (including citalopram), escitalopram pro-
vides relevantly better effects. Consequently, escitalo-
pram has been rather aggressively marketed as a superior 
treatment of depression (18) with a resulting remarkable 
sales growth paralleled by a drop in citalopram use over 
the past seven years worldwide (19). The clinical obser-
vations were ascribed to the fact that the R-(-)-enantio-
mer was not just an inactive by-stander, but rather that 
it interfered with the activity of the S-(+)-enantiomer 
(2). On the other hand, several independent analy-
ses, although recognizing numerical trends or statistical 
significance of certain differences, remained restrained 
regarding practical relevance of escitalopram vs citalo-
pram differences (eg 20-22, ). Moreover, a recent direct-in-
direct (“network”) meta-analysis found no significant dif-
ference between the two drugs regarding response rates 
(efficacy) or discontinuation rates (tolerability) (21). Other 
authors (23) have explicitly pointed-out certain inconsis-
tency in the observations/claims about the escitalopram-
citalopram differences, such as superior efficacy of escital-
opram vs citalopram in “moderately ill” but not “severely ill” 
patients (2,89 or just the opposite (12,13,15), and/or con-
cluded that the differences between the two drugs were 
below practical relevance (23-27).
With such contradictory messages and with emerging 
awareness that we have been overestimating the efficacy 
of antidepressants (28-30), it seemed plausible to re-visit 
the trial data and try to estimate the size and clinical rele-
vance of differences between escitalopram and citalopram 
in MDD with a focus on contrasts between equimolar dos-
es and with regard to duration of treatment and initial dis-
ease severity.
MeThods
The present study was conceived as an analysis (and meta-
analysis, where appropriate) of randomized controlled tri-
als (RCT) directly comparing escitalopram and citalopram 
in depression. No indirect or combined direct-indirect 
comparisons between treatments were intended.
Literature search, trial selection, and quality assessment
The Cochrane review and meta-analysis of escitalopram 
for depression published in 2009 (22) was used to trace the 
6 trials that it embraced. The list of excluded studies was 
also checked. Reference lists of other recent reviews/meta-
analyses (14,15,17,21,24-27) were checked for information 
on potential additional trials of interest. Data on one un-
published trial (SCT-MD-02) were retrieved from the Food 
and Drug Administration assessment of escitalopram (11). 
This document provided additional information on 2 pub-
lished trials (6,7).
Searching Scopus and PubMed (October 2009) (“escitalo-
pram” [title, abstract, keywords]) and “randomized con-
trolled trial” [publication type]) retrieved a total of 256 and 
437 citations, respectively; a search of the Cochrane Cen-
tral Register of Controlled Trials (November 2009) (“esci-
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talopram AND citalopram” [title, abstract, keywords] AND 
“randomized controlled trial” [publication type]) retrieved 
114 citations; a search of the EBSCO Publishing Electronic 
Databases (November 2009) (“escitalopram” AND “citalo-
pram” AND “randomized controlled trial” AND “depression” 
[all text]) retrieved 377 citations. All titles and abstracts 
were checked for trials of potential interest.
The 6 trials embraced by the Cochrane group meta-analy-
sis (22) were all judged to be of fair quality by the Cochrane 
collaboration criteria (22) and were not further evaluated 
in this respect. Any additional trial that was to be included 
in the current analysis was to be assessed for quality by the 
same criteria (31).
outcomes of interest and data extraction
The current regulatory requirements (32) for antidepres-
sants are that shorter trials for initial treatment should have 
2 primary outcomes for assessment of efficacy, both based 
on a validated depression severity measuring scale (Mont-
gomery-Asberg depression rating scale [MADRS], Hamil-
ton depression rating scale [preferably the 17-item version, 
HAM-D17]) (33,34): reduction of symptom severity vs base-
line (a continuous variable) and a proportion of patients 
experiencing ≥50% reduction in disease severity (propor-
tion of responders) at endpoint. Changes in Clinical Glob-
al Impression of Disease Severity (CGI-S vs baseline) (35), 
although less specific for depressive symptoms than the 
abovementioned scales, provide useful information on pa-
tient clinical status (36) and are suggested (32) as a sec-
ondary indicator of efficacy. All efficacy analyses should 
employ the “intent-to-treat” and “last observation carried 
forward” principles (ITT-LOCF). Hence, the 3 measures of 
efficacy (ITT-LOCF) were planned to be evaluated in the 
current escitalopram vs citalopram comparison: a) mean 
change in symptom score as assessed by MADRS (or HAM-
D) vs baseline; b) response rates, ie, proportion of patients 
achieving ≥50% reduction in MADRS (or HAM-D) vs base-
line; and c) mean change in CGI-S score vs baseline. Where 
both MADRS and HAM-D were available, MADRS was pre-
ferred and HAM-D data were considered only if MADRS 
data were missing.
Since safety profiles of escitalopram and citalopram in MDD 
(in general and in comparison) are well-known, safety as-
sessment focused on discontinuation rates due to adverse 
events (AE) or lack of efficacy (or either). Safety population 
(all randomized patients who received at least one dose of 
study drug) served as a denominator.
Where data were presented only in graphical format, Dag-
ra software (Blue Leaf Software, Hamilton, New Zealand) 
that digitalizes drawings (in PDF or any other format) was 
used to recover numerical values.
Where standard deviations (SD) for “mean change vs base-
line” (MADRS, HAM-D, CGI-S) were missing, the preferable 
strategy was to recover them using the Cochrane method-
ology (31) from any of the following (if available): standard 
errors, confidence intervals, test statistic, or P values. Where 
no recovery was possible, SDs were imputed using either 
of 2 validated methods (37): imputation of pooled SD of 
all other treatment arms in the remaining included stud-
ies or imputation of SD “borrowed” from other trials (simi-
lar in design) or other meta-analysis. With SD imputation, 
care was taken to use the values that corresponded to the 
“flawed” report in treatment duration (eg, if SD was missing 
for a change at week 8, then the imputed SD had to reflect 
the SD of change at week 8). When there were multiple 
flaws in data reporting requiring several approximations 
(eg, low-quality graphical data on mean change with no 
information on variability), trial data were not used for this 
particular outcome. Where only mean between-treatment 
differences were reported but not actual treatment means, 
pooled SD was recovered (as described) and used to deter-
mine effect size for use in meta-analysis.
data evaluation and synthesis
Where data from more than one trial were available, ran-
dom effects meta-analysis of the efficacy and safety out-
comes was conducted using StatsDirect software, version 
2.7.7. (StatsDirect Ltd, Altrincham, UK) that is based on the 
methodology of the Cochrane collaboration and was em-
ployed in some of the meta-analysis cited here (eg 24-26, ). 
All estimates of between-treatment differences are report-
ed with 95% confidence intervals (CI). Differences in “mean 
changes vs baseline” are expressed as mean difference (sin-
gle trial) or weighted mean difference (WMD, from meta-
analysis) and also as a standardized mean difference (SMD) 
(wherever possible). The criteria for assessment of clinical 
relevance were: a) for MADRS, 2 scale points as a limit of 
a relevant difference (mean, WMD) in reduction since it is 
considered as “minimally important difference” (17); b) for 
CGI-S, a difference between treatments in change vs base-
line (mean or WMD)≥0.33 scale points was arbitrarily cho-
sen as practically relevant (ie, differences ≤0.32 are prac-
tically irrelevant); c) for SMD (any instrument), the value 
of 0.32 as a limit of “small effect size” (ES) was used as 
a limit of relevance: practically/clinically relevant if 
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>0.32; as opposed to ES≥0.5 suggested as “clinically rele-
vant” by the guidance on depression by the National Insti-
tute for Clinical Excellence, NICE (1). Differences between 
responder rates (meta-analysis based on the exact meth-
od) are expressed as relative risks (RR). Analysis of odds ra-
tios, likely due to very different response rates in different 
trials, yielded rather high inconsistency. Numbers needed 
to treat to benefit (NNTB) based on absolute risk differenc-
es are provided as well. The approximate milestone for as-
sessment of clinical relevance was the suggestion by NICE 
that for antidepressants NNTB should be considered clini-
cally relevant if <10 (1). Differences in discontinuation rates 
due to AEs/inefficacy are presented as RR. For trials with 
one or both empty cells, continuity correction of 0.5 was 
applied (38).
Efficacy comparison was done at different time points 
(treatment duration) since trials differed in duration and 
some trials provided information at additional time points 
(besides the endpoint). However, each time point analysis 
was a separate one, and multiple time point data from one 
trial were never included in the same analysis (31). Con-
secutive analyses performed at different time points may 
generate the multiplicity problem that might reflect on in-
terval estimation (not only on P values) (31). The decision 
to perform such analyses was based on the reasoning that 
“mixing” data from different time points (eg, week 4 and 
week 8) or collapsing them into broader categories (eg, up 
to week 4, 6-8 weeks) might be less informative from the 
viewpoint of assessing practical/clinical relevance.
A comparison between escitalopram and citalopram was 
attempted also specifically for “severe patients” (typically 
defined as those with MADRS≥30 at baseline). However, 
since individual patient data were not available and due to 
a paucity of data in this setting (only 1 RCT, other data in-
clude subgroup/post-hoc analyses), only approximations 
were possible.
ResuLTs
Trials
A total of 7 trials were included, ie, 1 additional (39) (Table 
1) as compared with the most recent meta-analysis pub-
lished in 2009 (22). The additional trial (39) was also indus-
try-sponsored, but not by the originator of citalopram and 
escitalopram. Its quality is limited mainly due to selective 
reporting: no numerical data for post-baseline depres-
sion scale (HAM-D17) and CGI-S scores were provid-
ed, no measures of variability were reported, and graphical 
presentation of means did not allow for a reasonably reli-
able data extraction (39).
All trials were double-blind, parallel group multicentric 
RCTs conducted at different geographical locations and 
included adult, otherwise healthy, and mainly younger 
out-patients with MDD free of other psychopathology (Ta-
ble 1). They differed in duration (minimum 4, maximum 
24 weeks) (Table 1) and primary objectives (superiority of 
escitalopram vs placebo, non-inferiority or superiority vs 
citalopram) (Table 1). Fixed doses of either drug (no dose-
adjustment) were delivered in 4 trials, whereas dosing was 
flexible (initial doses could be doubled depending on re-
sponse/tolerability) in 3 trials (Table 1). Of those, average 
delivered doses were reported in 2 trials (7,11) and could 
be judged as equimolar, whereas in the third trial (39) the 
proportion of patients with increased doses was roughly 
comparable for the escitalopram and citalopram treatment 
arms (Table 1). Five trials were multi-arm (placebo and/or 
an additional dose of either drug or an additional active 
treatment), but the current evaluation focused on equimo-
lar escitalopram vs citalopram treatment arms (Table 1). In 
all trials, efficacy was assessed based on the intent-to-treat 
(ITT, all patients receiving at least one dose of study drug 
and having at least one post-baseline evaluation) data set 
with employment of the last observation carried forward 
principle, whereas safety assessment considered all pa-
tients receiving at least one dose of study drug (Table 1). 
Depression was quantified using MADRS in 6 trials and us-
ing HAM-D17 in 1 trial (Table 1). Each trial provided informa-
tion about at least one efficacy outcome on at least one 
additional time point besides the endpoint (Table 2).
efficacy comparison of escitalopram and citalopram
Figure 1 summarizes escitalopram vs citalopram differ-
ences in MADRS reduction and response rates by evalu-
ation time point. Web extra material 1 (MADRS reduction) 
and web extra material 2 (response rates) provide details 
on individual trial data and conducted meta-analysis. Fig-
ure 2 shows individual trial data and meta-analysis of CGI-S 
change vs baseline at week 8.
MAdRs change vs baseline
MADRS reduction with escitalopram was consistently 
greater than with citalopram at weeks 1, 4, 6, 8, and 24 
(Figure 1). However, 95% CI around WMD was entirely or 
almost entirely below 2 points at all times except week 
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6 (largely below 2 points), and 95% CI around SMD was 
practically entirely below 0.32 at all time points (Figure 1). 
Confidence intervals around mean or standardized mean 
between-treatment differences at weeks 1, 4, and 6 were 
entirely or largely below the limits of “relevance” for all in-
dividual trials except for one (10) (web extra material 1). At 
week 6 (endpoint), point-estimates in this particular trial 
were largely in the range of “practically relevant” and were 
the source of mild to moderate inconsistency (web extra 
material 1). At week 8, 95% CI around all individual stan-
dardized between-treatment differences were entirely or 
largely below the limit of “relevance” (web extra material 
1). Only one trial yielded a mean difference point-estimate 
larger than 2 scale points (-2.1 in the trial by Moore et al [9], 
borderline significant) (web extra material 1).
The 4-week trial based on HAM-D17 (39) and not included 
in this meta-analysis (no numerical data reported, no mea-
sures of variability) provided a graphical representation of 
changes vs baseline at weeks 1,2, 3, and 4 with complete-
TAbLe 1. Main characteristics of individual trials comparing escitalopram (esC) and citalopram (CIT) in treatment of major depressive disorder 
(Mdd)*
Author 
(reference) design/setting Aim Patients
Treatment arms (mg/d) 
n = ITT (LoCF)/safety
baseline MAdRs (ITT) 
(mean±sd)
dosing
(mg/d)
Burke (6) parallel DB, RCT
MC, USA
1 week placebo run-in
8 weeks treatment
psychiatrists
Superiority ESC vs 
placebo
Otherwise healthy MDD 
outpatients (DSM-IV), 
MADRS≥22, age 18-65, no 
other psychopathology
placebo: n = 119/122
ESC 10: n = 118/119
ESC 20: n = 123/125†
CIT 40: n = 125/125†
29.5 ± 5.0
28.0 ± 4.9
29.2 ± 4.6
29.2 ± 4.5
Fixed
1st week 10, 
then 20
1st week 20, 
then 40
Lepola (7) parallel DB, RCT
MC, Canada & EU
1 week placebo run-in
8 weeks treatment
primary care
Superiority ESC vs 
placebo
Otherwise healthy MDD 
outpatients (DSM-IV), 
MADRS 22-40, age 18-65, no 
other psychopathology
placebo: n = 154/154
ESC 10-20: n = 155/155†
CIT 20-40: n = 159 / 160†
28.7 ± 4.0
29.0 ± 4.3
29.2 ± 4.2
Flexible –ESC 
10, CIT 20 
could double 
at week 4/6
Mean: 14.0
Mean: 28.4
SCT-MD-02 (11) parallel DB, RCT
MC, USA
1 week placebo run-in
8 weeks treatment
psychiatrists
Superiority ESC vs 
placebo
Otherwise healthy MDD 
outpatients (DSM-IV), 
MADRS≥22, age 18-80, no 
other psychopathology
placebo: n = 125 / 127
ESC 10-20: n = 124 / 125†
CIT 20-40: n = 119 / 123†
28.8 ± 5.0
28.7 ± 4.3
28.3 ± 5.0
Flexible –ESC 
10, CIT 20 
could double 
at week 3-8
Mean: 17.6
Mean: 35.3
Lalit (39) parallel DB, RCT
MC, India
placebo run-in
4 weeks treatment
psychiatrists
Not clearly defined. 
Likely inequality 
ESC/CIT/SER
Otherwise healthy MDD 
outpatients (ICD-10), HAM-
D17≥18, age 18-65, no other 
psychopathology
ESC 10-20: n = 69/69†
CIT 20-40: n = 74/74†
SER 100: n = 71/71
HAM-D17
26 ± 6
25 ± 5
25 ± 4
Flexible – ESC 
10, CIT 20 
could double 
at week 2
42% at 20 mg
51% at 40 mg
Colonna (8) parallel DB, RCT
MC, EU
1 week placebo run-in
24 weeks treatment
primary care
Non-inferiority ESC 
vs CIT
Otherwise healthy MDD 
outpatients (DSM-IV), 
MADRS≥22, age 18-65, no 
other psychopathology.
ESC 10: n = 165/175†
CIT 20: n = 174/182†
29.8±not reported
29.8±not reported
Fixed
Moore (9) parallel DB, RCT
MC, France
8 weeks treatment
psychiatrists and 
primary care
Superiority ESC 
vs CIT
Otherwise healthy MDD 
outpatients (DSM-IV), 
MADRS≥30, age 18-65, no 
other psychopathology.
ESC 20: n = 138 142†
CIT 40: n = 142/152†
36.3 ± 4.8
35.7 ± 4.4
Fixed
1st week 10, 
then 20
1st week 20, 
then 40
Yevtushenko (10) Parallel DB, RCT
MC, Russia
6 weeks treatment
psychiatrists
Superiority ESC 
vs CIT
Otherwise healthy MDD 
outpatients (DSM-IV), 
MADRS≥25, age 25-45, no 
other psychopathology.
ESC 10: n = 108/108†
CIT 10: n = 106/106
CIT 20: n = 108/108†
34.8 ± 3.5
35.4 ± 3.3
35.7 ± 3.8
Fixed
*Abbreviations: ITT – intent-to-treat; LoCF – last observation carried forward; MAdRs – Montgomery-Asberg depression Rating scale (33); db – double-blind; RCT 
– randomized controlled trial; MC – multicentric; usA – united states of America; dsM-IV – diagnostic and statistical Manual of Mental disorders, 4th edition (40); eu 
– european union; sd - standard deviation; seR – sertralin; ICd-10 – International Classification of diseases and Related health Problems, 10th revision (41); hAM-d17 
– 17-item hamilton depression Rating scale (34).
†Comparison of interest for the current evaluation (equimolar doses).
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ly overlapping mean values for escitalopram and citalo-
pram.
Response rates
Response rates were based on MADRS in all trials except 
one (HAM-D17). Apart for week 8, data are scarce (Figure 1). 
At week 8, with mild inconsistency, “risk” of response was 
significantly higher with escitalopram (pooled RR around 
1.14) (Figure 1). However, NNTB was below the limit of 
“practical relevance” (Figure 1). Only one trial (Moore et al 
[9]) out of 5 yielded a significant RR and an NNTB approach-
ing “clinical relevance” (web extra material 2). Pooled esti-
mates at week 2, 4, and 6, each based on 2 RCTs, are diffi-
cult to interpret. As shown in web extra material 2, at each 
time point, one of the trials yielded response rates that 
were for both drugs 2 to 4 times lower than in the other 
considered trial. Proportion meta-analysis indicates non-
combinability of such proportions for either drug at any of 
these time points (P < 0.001 based on Cochran Q). There-
fore, from the practical standpoint it appears more infor-
mative to consider each trial separately based on NNTB: 
at week 2, both trials indicate no relevant difference; at 
week 4, both trials indicate no relevant difference; at week 
6, one trial indicates no relevant difference, whereas the 
other one indicates a difference “approaching relevance” 
(web extra material 2).
CGI-s change vs baseline
At week 8, with mild inconsistency, the 95% CIs around 
pooled WMD and SMD were entirely well below the lim-
its of practical relevance (Figure 2). Also, mean and stan-
dardized between-treatment differences were entirely or 
largely below the limits of relevance for each individual 
trial (Figure 2).
TAbLe 2. Availability of information on efficacy outcomes based on intent-to-treat with last observation carried forward data by trial*
Author (reference)
burke (6) Lepola (7) sCT-Md-02 (11) Lalit (39)† Colonna (8) Moore (9) Yevtushenko (10)
used data:
published + + – + + + +
unpublished + + + – – – –
Duration (weeks) 8 8 8 4 24 8 6
MAdRs change:
week 1 + + + – – + +
week 4 + + + – – + +
week 6 + + + – – – +
week 8 + + + – + + –
week 24 – – – – + – –
Variability SD SD SD – from CI, imput‡ from P from SE§
Response rates:
week 2 – + – + – – –
week 4 – + – + – – –
week 6 – + – – – – +
week 8 + + + – + + –
week 24 – – – – + – –
CGI-s change:
week 6 – – – – – – +
week 8 + + + – + + –
week 24 – – – – + – –
Variability from SE imput from SE – imput, from PII from P from SE
*Abbreviations: MAdRs – Montgomery-Asberg depression Rating scale (33); sd – standard deviation; se – standard error; CI – confidence interval; 
CGI-s – Clinical Global Impression-severity (35).
†hAM-d17 – 17-item hamilton depression Rating scale (hAM-d17) (34) was used for quantification of depression but, just as with CGI-s, no post-
baseline numerical data and measures of variability were reported. Graphical presentations did not allow for data extraction. Response was 
defined as ≥50% reduction in hAM-d17.
‡For week 24 sd recovered from CI of difference, for week 8 imputed (37).
§Numerical values reported for week 6, for weeks 1 and 4 mean and se graph-read.
IIFor week 8 sd imputed, for week 24 from P.
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Figure 1.
summary of escitalopram (esC) vs citalopram (CIT) differences in reduction of symptom severity (upper panel) and response rates (lower panel) at differ-
ent evaluation time points (weeks of treatment). upper left panel shows weighted mean difference (WMd) with a shaded area indicating the limit of “min-
imally important difference;” upper right panel shows standardized mean difference (sMd) with a shaded area indicating the limit of “small” effect size. 
Abbreviations: MAdRs – Montgomery-Asberg depression Rating scale (33); RCT – randomized controlled trial; RR – relative risk; NTT – number needed to 
treat. Asterisk – MAdRs was used in all trials except one (39) that used hAM-d17 (34) and provided data on response rates at week 2 and week 4.
Figure 2.
 Meta-analysis of escitalopram (esC) vs citalopram (CIT) differences in reduction of Clinical Global Impression-severity (CGI-s) (35) at week 8 vs baseline. 
Left panel shows weighted mean difference (WMd) with a shaded area indicating the limits of “practically relevant difference.” Right panel shows stan-
dardized mean difference indicating the limit of “small effect size.”
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The 4-week trial not reporting numerical values on CGI-S 
changes (39) includes a graphical representation of CGI-S 
change vs baseline at weeks 1, 2, 3, and 4 with completely 
overlapping values for escitalopram and citalopram.
One trial (total N = 216) reporting on week 6 (10) indicated 
a large difference in favor or escitalopram (mean, -0.55; 95% 
CI, -0.83 to -0.27; standardized, -0.53; 95% CI, -0.8 to -0.26).
One trial (total N = 339) reporting on week 24 (8), indicated 
a difference in favor of escitalopram, but largely below the 
limit of relevance (mean, -0.24; 95% CI, -0.55 to 0.07; stan-
dardized, -0.17; 95% CI, -0.38 to 0.05).
efficacy comparison of escitalopram and citalopram in 
patients with baseline MAdRs≥30
Only one RCT was conducted specifically in patients with 
baseline MADRS≥30 (“severely depressed”) and was includ-
ed in the main meta-analysis (Moore et al [9]). The main 
efficacy outcomes (Table 3) indicate a difference in favor 
of escitalopram that could be judged as “borderline practi-
cally relevant:” differences in MADRS (week 4, week 8) and 
CGI-S (week 8) reduction are largely below the limit of rel-
evance, but the responder rates (week 8) are higher with 
esctialopram with an NNTB “close to” clinical relevance.
One of the trials included in the main meta-analysis (Col-
onna et al [8]) provided separate data for a subgroup of 
severely depressed patients (finding practically identical 
results for all outcomes for the 2 drugs). An additional pub-
lication (13) reported on a post-hoc pooled analysis of pa-
tients with MARDS≥30 selected from 3 other trials includ-
ed in the present meta-analysis (6,7,11). None of these trials 
implemented stratified randomization regarding disease 
severity. Table 3 summarizes efficacy outcomes for pooled 
data from these 2 reports. All differences are in favor of es-
citalopram, but 95% CI around differences in MADRS and 
CGI-S reduction, as well as NNTB (response), are largely be-
low the limits of practical (clinical) relevance.
discontinuations due to Ae or inefficacy or either
With mild inconsistency, the risk of discontinuation of treat-
ment due to AE or inefficacy during the initial period of up 
to 8 weeks was slightly lower with escitalopram (Figure 3). 
The individual trial data vary from more than twice greater 
risk to more than twice lower risk with escitalopram (Fig-
ure 3). Discontinuations due to AE were infrequent with 
both drugs with practically no difference between them 
(Figure 3). Discontinuations due to inefficacy were twice 
more frequent with citalopram than with escitalopram, 
but the absolute numbers are very low, ie, 9/924 (0.97%) 
vs 4/899 (0.44%) and the difference could have been by 
chance (Figure 3).
Data for the period after week 8 come only from patients 
completing the first 8 weeks of treatment in the only 24-
week trial (8) (Figure 3). Discontinuations due to AE were 
apparently somewhat more frequent with citalopram, but 
the numbers were very low and the observed differences 
could have been by chance (Figure 3).
TAbLe 3. summarized efficacy differences (ITT-LoCF) between escitalopram (esC) and citalopram (CIT) in patients with severe depression (Mont-
gomery-Asberg depression rating scale [MAdRs] score ≥30)*
Week Moore (9)† (esC n = 138; CIT n = 142) Llorca (13), Colonna (8) (pooled esC n = 249; CIT n = 260)‡
Description RCT specifically in patients with MADRS≥30 Data on patients with MADRS≥30 selected from other RCTs 
with MADRS≥22 at inclusion
ECS-CIT MADRS reduction
Difference <0 favors ESC
4 Mean difference (95% CI) = -0.7 (-2.52 to 1.12)
Standardized (95% CI) = -0.090 (-0.324 to 0.145)
8 Mean difference (95% CI) = -2. 1 (-4.21 to 0.01)
Standardized (95% CI) = -0.233 (-0.468 to 0.002)
Pooled random WMD (95% CI) = -1.901 (-5.407 to 1.605)
Pooled random SMD (95% CI) = -0.172 (-0.490 to 0.146)
ESC-CIT CGI-S reduction
Difference <0 favors ESC
8 Mean difference (95% CI) = -0. 120 (-0.455 to 0.215)
Standardized (95% CI) = -0.084 (-0.318 to 0.151)
Pooled random SMD (95% CI) = -0.220 (-0.640 to 0.199)
ESC vs CIT response (MADRS)
RR>1 favors ESC
8 76.1% vs 61.3%
RR (95% CI) = 1.24 (1.06 to 1.47)
NNT = 7 benefit (4 benefit to 25 benefit)
Pooled random proportions 54.6% vs 45.7%
Pooled random RR (95% CI) = 1.184 (0.861 to 1.627)
Pooled random NNT = 12 benefit (4 benefit to 14 harm)
*Abbreviations: RCT – randomized controlled trial; WMd – weighted mean difference; sMd – standardized mean difference; CGI-s – Clinical Global Impression-se-
verity (35); RR – relative risk; NNT – number needed to treat; CI – confidence interval.
†one of the trials included in the main efficacy analysis.
‡Patients included in these reports are selected from RCTs based on MAdRs (33). None of the RCTs employed stratified randomization in respect to disease 
severity. Llorca (13) – post-hoc analysis of selected pooled data from burke (6), Lepola (7), and sCT-Md-02 (11) (esC n = 169, CIT n = 171); Colonna (8) – a subgroup of 
patients from an RCT (esC n = 80, CIT n = 89).
69Trkulja: Esctialopram vs Citalopram for Depression
www.cmj.hr
dIsCussIoN
Why look into escitalopram vs citalopram clinical trial 
data again?
Depression is common, seriously disabling, chronic in na-
ture and expensive disease – it is one of the leading causes 
of loss of disability-adjusted life-years world-wide with to-
tal costs amounting to hundreds of millions in any country 
or currency (1). Development of newer antidepressants has 
enabled wider use of pharmacological treatments for de-
pression. This valuable contribution has, however, turned 
depression into a premium marketing playground; most 
of the newer antidepressants are among top selling drugs 
world-wide with individual sales in billions (30). At the 
same time, there is growing evidence that benefits of an-
tidepressants have been considerably overestimated and 
that decisions on “who should be treated” and “which drug 
should be used” have been largely influenced by market-
ing efforts and less by evidence (28-30). In this context, the 
“story of escitalopram and citalopram” is a specific one since 
both were developed and marketed by the same compa-
ny. While there is a sound molecular rationale (2) to explain 
why should one expect more from the “pure active enan-
tiomer” (escitalopram) than from “active entantiomer in a 
racemic mixture” (citalopram) on equimolar basis, transla-
tion of this “marker-based reasoning” into clinical evidence 
is inevitably marketing-driven. Escitalopram came around 
at the time of expiration of exclusivity of citalopram and in 
order to keep the market share the manufacturer actually 
had to offer “something new and better.” Individually, trials 
comparing escitalopram and citalopram share common 
characteristics of clinical trials of antidepressants in gen-
eral (30) – they are mostly short and small – and their re-
sults are inconclusive regarding two important questions: 
a) What is the actual size of the between-drug differenc-
es? and b) What is their practical/clinical relevance? In an 
attempt to contribute to answering these questions, the 
present analysis had specific aims. First, it compared equi-
molar (S-[+]-enantiomer) doses. This decision was based 
on the following: a) the formal dosing recommendations 
for the two drugs reflect the concept of “proportionality” 
(3,4); b) although in practice the two drugs are likely used 
after other different modalities, there is no RCT that actu-
ally aimed to answer the question whether the “free (intui-
tive, unrestrained) use” of one drug provided a possibility 
of a better general control of depression than the other 
drug. Under such circumstances, inclusion of treatment 
arms with “non-equimolar” doses in between-drug com-
parisons could be a source of noise compromising the esti-
mation of size of the differences. Second, it included CGI-S 
as an efficacy outcome. Although CGI-S is not appropri-
ate to serve as a single instrument in trials evaluating po-
tential antidepressant compounds, it is sensitive enough 
as to capture the effects of antidepressants and pro-
vides robust information on changes in clinical sta-
Figure 3.
Comparison of escitalopram (esC) vs citalopram (CIT) regarding discontinuation of treatment due to adverse events (Ae) or inefficacy or either. Asterisk in-
dicates data from 4 to 8 week trials. data from the 24-week trial (8) are also included since the report allowed for a distinction of withdrawals that occurred 
before week 8 and after week 8. dagger indicates data for patients reported to have completed the first 8 weeks of treatment in the 24-week trial (8).
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tus of depressed patients that is useful for evaluations in 
daily practice (36,42,43). In this respect, it is a valuable aid 
in an attempt to estimate clinical relevance of differences 
between two established antidepressants. Third, it assesses 
differences at several time points. Although this could be a 
source of a multiplicity problem (31), it could also allow for 
a more reliable assessment of treatment differences than 
comparisons based on a single-point measurement of an 
outcome susceptible to fluctuation.
size and practical relevance of efficacy differences 
between escitalopram and citalopram
Assessing clinical relevance is a largely arbitrary effort par-
ticularly in depression (30), but the criteria used in the 
present assessment referring to MADRS reduction, NNT, 
and effect size are generally accepted as reasonable. The 
only arbitrary criterion was that referring to the difference 
in GGI-S reduction – if ≤0.32 scale points (ie, less than 1/3 
of a point) then it is irrelevant. With CGI-S being an ordinal 
scale, it seems reasonable to consider that in order to fall 
into the next upper or lower level (category), the “severity” 
needs to change to the extent that reaches at least “half 
the way” toward this next step (ie, “half a point”). Hence, 
excursions (from the actual level) that are less than 1/3 of 
the “way towards the next level” are unlikely to result in a 
change in CGI-S grading and could be considered not clin-
ically relevant.
In line with the molecular background, escitalopram pro-
vided greater MADRS reduction, higher proportion of re-
sponders and, less so, a greater reduction in CGI-S. By their 
sizes, however, all the differences could be judged as being 
below clinical/practical relevance. Data are most abundant 
for MADRS reduction. At all time points (1, 4, 6, 8, and 24 
weeks), 95% CI around effect sizes were within the range 
of “small.” Similarly, 95% CI around mean differences were 
consistently entirely (or nearly so) below the limit of a “min-
imally important difference” (2 points). Only at week 6 was 
the pooled estimate “shifted” somewhat toward the limit 
of “relevance.” It should be noted, however, that in one of 
the trials (8) that was conceived as a non-inferiority trial (for 
escitalopram vs citalopram), the acceptance limit for differ-
ence in MADRS was set at 3 points. By this criterion, and 
with a “reverse logic,” the present data suggest that cital-
opram is non-inferior to escitalopram regarding MADRS 
reduction – over the entire short-to-medium-term treat-
ment. Regarding the response rates and CGI-S reduction, 
only at week 8 were the comparisons based on a rea-
sonable amount of data. Escitalopram is apparent-
ly associated with a higher “risk” of being a responder by 
week 8 of treatment. Although inconsistency in meta-anal-
ysis of response rates was mild, this conclusion is largely in-
fluenced by the trial that included only severely depressed 
patients (9). However, even this estimate does not support 
a conclusion of practical relevance since NNTB was 14 with 
95% CI extending from 7 to 111. If the estimate is accurate, 
additional studies in, eg, a prospective cumulative meta-
analysis, would improve its precision (shorten the confi-
dence interval), but point-estimate is not likely to fall be-
low 10. The findings of a recent network meta-analysis (21) 
(ie, a direct-indirect comparison based on a larger number 
of trials) support such a conclusion – it yielded an odds ra-
tio of “response” that corresponds to an NTTB of 25 (assum-
ing the citalopram response rate of 50%) with CI extending 
from benefit to harm.
The differences between two treatments were lowest re-
garding reduction of CGI-S. Confidence intervals around 
pooled WMD and effect size were not only below 0.32, but 
were below 0.25 (less than 1/4 of a point or far lower than 
the limit of a “small” effect size). The escitalopram vs citalo-
pram differences in all 3 efficacy measures appeared great-
est at week 6. They were all largely influenced by one same 
6-week trial conducted in Russia (Yevtushenko et al [10]). 
This particular trial differed from all the others providing 
6-week or 8-week data in that MADRS reduction, response 
rates, and CGI-S reduction were by far greater for both 
drugs, and in that the differences between the two drugs 
were by far larger. The specificity of the trial was that it in-
cluded only patients 25-45 years of age with MADRS≥25. In 
this respect, the results could actually be more informative 
about the sample than about the general between-treat-
ment relationship.
The basis for evaluation of escitalopram and citalopram in 
severely depressed patients (typically, MADRS≥30) is very 
modest – there is only one RCT specifically addressing the 
issue (9). It showed a greater “risk” of being a responder at 
week 8 associated with escitalopram, but did not unequiv-
ocally support a conclusion of relevant superiority. NNTB 
was 7 (95% CI, 4 to 25), thus being “close to relevant,” but 
there was practically no difference between treatments in 
CGI-S reduction, practically no difference in MADRS reduc-
tion at weeks 1 and 4, whereas the difference at week 8 
(and particularly the standardized difference) was largely 
below the limits of relevance. Other data on “severe pa-
tients” (extensively exploited in various reviews) are actu-
ally only supportive: one of the trials (8) reported on a sub-
group of such patients and an additional report (13) was a 
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post-hoc analysis of patients selected from 3 other RCTs (all 
trials without stratified randomization). The present pooled 
estimates based on this data were in favor of escitalopram, 
but did not, by size, support a conclusion of “relevance.” An-
other analysis of these same data (12) demonstrated a sig-
nificant trend of increasing between-treatment differenc-
es in patients with higher MADRS. For example, for a small 
subgroup of patients (90 in total) with MADRS≥35, escitalo-
pram vs citalopram difference in MADRS reduction at week 
8 was estimated to be 6 points. However, the confidence 
interval extended from around 0.1 to 13. Overall, it appears 
plausible to conclude that in more severely ill patients the 
differences in efficacy between escitalopram and cital-
opram could be expected to be larger – still, it does not 
mean that they would be clinically/practically relevant.
Comparative safety and discontinuations due to Ae and 
inefficacy
The considered trials are by size and duration by far too 
small of a basis for “final” evaluation of safety of the two 
drugs. However, they are useful for a direct safety profile 
comparison “under identical conditions.” A detailed analy-
sis by the Cochrane group (22) showed no relevant differ-
ence between the two drugs in respect to total incidence 
of AEs or incidence of any individual AE. For antidepres-
sants, discontinuation of treatment is a major factor of suc-
cess or failure since the disease typically requires sustained 
treatment. In a drug comparison setting, discontinuations 
due to AE and/or inefficacy are particularly interesting as 
they are directly “linked” to the drug and could be accu-
rately recorded in formal double-blind RCTs. The Cochrane 
meta-analysis (22) reported on these outcomes (with no 
significant or relevant difference between the drugs), 
but pooled together all trial data irrespective of their du-
ration, included also “non-equimolar” doses and used “all 
randomized” patients as a basis. The present overview 
separates discontinuations during the short-term (up to 8 
weeks) and medium-term (week 9 to 24) treatment, stays 
with equimolar doses (which were also compared for effi-
cacy), and uses “safety” data sets as the basis. Under these 
conditions, there was no relevant difference between the 
treatments regarding short-term discontinuations due to 
AE or inefficacy (cumulatively) or due to AEs. Discontinu-
ations due to inefficacy were almost twice more frequent 
with citalopram, but the numbers were very low (0.4% and 
0.9%) and inconclusive. Data for week 9 to 24 are actually 
limited to around 300 patients that completed the first 8 
weeks in the single 24-week trial (8) and are too scarce for 
any reasonable conclusion.
Clinical relevance is not only about effect size
We seem to have built (or have allowed it to be built) a “cul-
ture of antidepressant clinical trials” which, due to a number 
of reasons (overall trial design and analysis issues, patient 
selection, (un)publishing policies, data “furnishing,” regula-
tory (non)submissions, industry influence), produces results 
that do not reflect the real physical world that these drugs 
are intended for (30,44). First, effects sizes are inflated sug-
gesting that there is more benefit in these drugs than there 
really is. Second, generalizability of these trials is, at best, 
very modest – according to a “typical” RCT of an antidepres-
sant (and this applies to the trials addressed in this over-
view, as well), the drug would actually be intended only for 
generally younger, moderately to severely ill MDD patients 
(as assessed on a depression measuring scale), with moder-
ately long disease history, who, in general, had not received 
previous treatment and are free of other psychopathology 
or comorbidity (30,44). Comparing antidepressants based 
on such trials with the aim of selecting the “right one” for 
the general population is inherently problematic (44). A 
truly meaningful evaluation of antidepressants in general 
and in comparisons would require pragmatic trials that are 
compliant with the nature of the disease and characteristics 
of the targeted population (30,44). Hence, in respect to the 
“general population,” clinical relevance of escitalopram vs 
citalopram differences in treatment of depression is limited 
not only by the small effect sizes but also by the general 
characteristics of the existing trials.
In conclusion, existing RCTs do not support the claim 
about clinically relevant superiority of escitalopram over 
citalopram (on equimolar basis) in short-term (4-8 weeks) 
or medium-term (up to 24 weeks) treatment of MDD. Data 
addressing specifically only “severe” patients (MADRS≥30) 
are scarce and currently inconclusive. They do indicate a 
possibility of consistent and larger differences in favor of 
escitalopram, but this is yet to be formally demonstrated.
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